简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2018-10-29 15:36 Takeda Announces Execution of Senior Short Term Loan Facility Agreement and Subordinated Syndicated Loan Agreement and Second Amendment to Bridge Credit Agreement in Connection with Proposed Acquisition of Shire plc
2018-10-26 14:12 Harvest Enterprises Inc. Announces Appointments of Elroy Sailor and Mark Barnard to Its Board of Directors
2018-10-26 14:06 PHC Holdings Announces Strategic Cooperation Agreement with Mitsui & Co., Ltd. and China Resources Healthcare Group Limited
2018-10-25 13:53 Eminent Scientist James Till Turned Philanthropist; Donates Prize Money to the Cause of Young Researchers
2018-10-25 13:41 Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains
2018-10-24 16:36 PotNetwork Holdings, Inc. Reports $18.1 Million in Sales Surpassing Entire Revenue Generated in 2017
2018-10-24 16:34 Mentice Appoints New Member to its Board of Directors.
2018-10-24 11:40 ResMed Wins German Patent Infringement Case Against Fisher & Paykel
2018-10-23 15:05 Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
2018-10-23 10:53 Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product
2018-10-22 16:20 Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA®▼ (Tivozanib) for Patients with Advanced Renal Cell Carcinoma
2018-10-22 13:43 Edogawa Niche Prize 2018 to Be Awarded to Prof. James Till for Stem Cell Discovery
2018-10-22 13:40 Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
2018-10-22 10:05 PotNetwork Holdings, Inc. Concludes Record Breaking 3rd Quarter with Revenues Exceeding $6.1 Million
2018-10-19 18:27 Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
2018-10-19 16:54 Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc
2018-10-18 14:18 Brightree Launches First Patient App for HME
2018-10-17 16:02 AirFit F30, ResMed’s First Minimal-Contact Full Face CPAP Mask, Now Available in the U.S., Canada
2018-10-17 15:08 PotNetwork Holdings, Inc. Releases PCAOB Fully Audited and Reviewed Financial Statements under Its Registration as an SEC Reporting Company
2018-10-17 13:51 Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health

Business Wire Weibo

Press Releases

Latest Releases